# Afynia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/afynia

- Industry: Medical Devices & Equipment
- Headquarters: Canada
- Website: www.afynia.com/
- Total disclosed funding: $5M
- Latest round: Seed (Feb 25, 2025)
- Investors on record: 5

## About

Afynia is a Canadian company specializing in advanced diagnostic solutions for endometriosis, focusing on innovative tests that streamline the diagnostic process for chronic pelvic pain.Founded in 2021, Afynia, previously known as AIM, develops diagnostic tools for endometriosis. The company is headquartered in Canada and has completed a total of 3 deals. Warren Foster, the CEO and founder, has a background in innovating healthcare solutions. In its latest funding round, Afynia raised USD 5.00 mn in Seed funding on February 25, 2025, led by Bio-Rad Laboratories, Inc., with participation from other investors including Capital Angels Network, Gaingels, Impact America Fund, and SOSV. This round marked the total amount raised by Afynia at USD 5.00 mn.Afynia specializes in the development and provision of advanced diagnostic solutions for endometriosis, primarily through its flagship product, the EndomiR Test. This innovative test analyzes circulating microRNAs (miRNAs) to identify differential expression levels associated with endometriosis, providing healthcare professionals with a crucial tool for diagnosing this often-overlooked condition. The EndomiR Test is targeted towards OB-GYNs and healthcare providers across North America and Europe, addressing the needs of millions affected by endometriosis, and seeks to minimize the lengthy diagnostic journey faced by patients.Afynia generates revenue through its EndomiR Test, which is sold directly to healthcare professionals. The company's transaction structure is centered around B2B relationships, where physicians and clinics order tests for their patients, facilitating a straightforward billing process. The revenue model may include partnerships with healthcare providers to enhance the availability of testing services, allowing Afynia to deliver essential resources for the effective diagnosis and management of endometriosis.Following its recent Seed funding of USD 5.00 mn raised on February 25, 2025, Afynia plans to utilize these resources to further develop its blood test for endometriosis. The company is focused on expanding its market presence in North America and Europe, aiming to introduce new products that will enhance diagnostic capabilities. Specific timelines for these product launches will be determined as development progresses.

## Funding rounds

- Seed, Feb 25, 2025, $5M — SOSV, Bio-Rad Laboratories, Inc., Impact America Fund, Gaingels, Capital Angels Network

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- Bio-Rad Laboratories, Inc. — Seed
- Impact America Fund (https://capitalatlas.ai/funds/impact-america-fund) — Seed
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed
- Capital Angels Network — Seed